Exact Mass: 359.2460308000001
Exact Mass Matches: 359.2460308000001
Found 416 metabolites which its exact mass value is equals to given mass value 359.2460308000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
napelline
LSM-1634 is a kaurane diterpenoid. Napelline is a natural product found in Aconitum karakolicum, Aconitum baicalense, and other organisms with data available. 12-Epinapelline is a kaurane diterpenoid. 12-Epinapelline is a natural product found in Aconitum napellus, Delphinium leroyi, and other organisms with data available. Annotation level-1 12-Epinapelline is a diterpene alkaloid isolated from Aconitum baikalense. 12-Epinapelline exhibits Anti-inflammatory activity and stimulates the growth of colonies from fibroblast precursors[1][2]. 12-Epinapelline is a diterpene alkaloid isolated from Aconitum baikalense. 12-Epinapelline exhibits Anti-inflammatory activity and stimulates the growth of colonies from fibroblast precursors[1][2].
Lavoltidine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
2-Hydroxylauroylcarnitine
C19H37NO5 (359.26715920000004)
2-Hydroxylauroylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxylauroylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-hydroxylauroylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
3-hydroxydodecanoyl carnitine
C19H37NO5 (359.26715920000004)
3-Hydroxydodecanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodecanoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxydodecanoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Undecanedioylcarnitine
Undecanedioylcarnitine is an acylcarnitine. More specifically, it is an undecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
12-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
12-hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 12-hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
7-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
10-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
10-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 10-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
6-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
6-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
11-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
11-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 11-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
5-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
8-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
8-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
4-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
4-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-Hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
9-Hydroxydodecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-Hydroxydodecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Hydroxydodecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Hydroxydodecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Palmitoyl Cysteine
C19H37NO3S (359.2494012000001)
N-palmitoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Myristoyl Methionine
C19H37NO3S (359.2494012000001)
N-myristoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Methionine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
N-Eicosapentaenoyl Glycine
N-eicosapentaenoyl glycine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Glycine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Eptastigmine
C21H33N3O2 (359.25726380000003)
Gepirone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Gepirone is a selective and affinitive 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research[1].
Glycyllysylarginine
C14H29N7O4 (359.22809140000004)
N-Methylrosmaricine
C21H29NO4 (359.20964740000005)
N-methylrosmaricine is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). N-methylrosmaricine can be found in rosemary, which makes N-methylrosmaricine a potential biomarker for the consumption of this food product.
7alpha-Hydroxyparavallarine
A natural product found in Kibatalia laurifolia.
(E)-methyl 4-(2-acetyl-4-oxonon-1-enyl)-6-propylnicotinate|Monasnicotinate D
C21H29NO4 (359.20964740000005)
3beta-(dimethylamino)-pregn-5-en-16-one-20-ol|terminamine I
trichosetin
C21H29NO4 (359.20964740000005)
A member of the class of octahydronaphthalenes that is (2R,4aS,5R,6R,8aS)-2,5-dimethyl-6-[(1E)-prop-1-en-1-yl]-1,2,3,4,4a,5,6,8a-octahydronaphthalene in which the hydrogen at position 5 has been replaced by a (Z)-hydroxy[(5S)-5-(hydroxymethyl)-2,4-dioxopyrrolidin-3-ylidene]methyl group. Produced by the dual culture of Trichoderma harzianum and Catharanthus roseus callus, it exhibits significant antimicrobial activity against Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis.
Luciculine
Origin: Plant; Formula(Parent): C22H33NO3; Bottle Name:Napelline; PRIME Parent Name:Napelline; PRIME in-house No.:V0349; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid
Ala Ala Ala Lys
C15H29N5O5 (359.21685840000004)
Ala Ala Lys Ala
C15H29N5O5 (359.21685840000004)
Ala Lys Ala Ala
C15H29N5O5 (359.21685840000004)
Gly Gly Lys Val
C15H29N5O5 (359.21685840000004)
Gly Gly Val Lys
C15H29N5O5 (359.21685840000004)
Gly Lys Gly Val
C15H29N5O5 (359.21685840000004)
Gly Lys Val Gly
C15H29N5O5 (359.21685840000004)
Gly Val Gly Lys
C15H29N5O5 (359.21685840000004)
Gly Val Lys Gly
C15H29N5O5 (359.21685840000004)
Lys Ala Ala Ala
C15H29N5O5 (359.21685840000004)
Lys Gly Gly Val
C15H29N5O5 (359.21685840000004)
Lys Gly Val Gly
C15H29N5O5 (359.21685840000004)
Lys Val Gly Gly
C15H29N5O5 (359.21685840000004)
Val Gly Gly Lys
C15H29N5O5 (359.21685840000004)
Val Gly Lys Gly
C15H29N5O5 (359.21685840000004)
Val Lys Gly Gly
C15H29N5O5 (359.21685840000004)
CAR 12:0;O
C19H37NO5 (359.26715920000004)
(2S)-2-[bis(3,5-dimethylphenyl)-methoxymethyl]pyrrolidine,hydrochloride
C22H30ClNO (359.20158000000004)
(S,S)-3-CBZ-3,6-DIAZABICYCLO[3.2.0]HEPTANE
C21H33N3O2 (359.25726380000003)
Cyclomethycaine
C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
2a,3a-Epoxy-16b-(1-pyrrolidinyl)-5a-androstan-17b-ol
tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[5-(4-methylpiperazin-1-yl)-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
C18H26BN3O4 (359.20162660000005)
2,4-Diamino-6-[2-(2-Undecyl-1-Imidazolyl)Ethyl]-1,3,5-Triazine
PIFZER CALCIUM-SENSING PARATHYROID HORMONE RECEPTORS ANTAGONISTS
Tert-Butyl 6-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)-3,4-Dihydroisoquinoline-2(1H)-Carboxylate
2-(3,4-Dimethoxyphenyl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylethanamine
C21H29NO4 (359.20964740000005)
cannabigerolate
A dihydroxybenzoate that is the conjugate base of cannabigerolic acid, obtained by deprotonation of the carboxy group.
Cannabinerolate
A dihydroxybenzoate that is the conjugate base of cannabinerolic acid, obtained by deprotonation of the carboxy group.
(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosa-4,7,10,13,15,19-hexaenoate
Ursocholanate
C24H39O2- (359.29498939999996)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
9alpha-Hydroxy-3-oxo-23,24-bisnorchol-4-en-22-oate
(9Z,12Z,15Z,18Z)-tetracosatetraenoate
C24H39O2- (359.29498939999996)
A polyunsaturated fatty acid anion that is the conjugate base of (9Z,12Z,15Z,18Z)-tetracosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Cholanate
C24H39O2- (359.29498939999996)
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Leu-Leu-Asp
C16H29N3O6 (359.20562540000003)
A tripeptide composed of two L-leucine units joined to L-aspartic acid by a peptide linkage.
Glu-Ile-Val
C16H29N3O6 (359.20562540000003)
A tripeptide composed of L-glutamic acid, L-isoleucine and L-valine joined in sequence by peptide linkages.
5-(diethylamino)-2-[(E)-(diphenylhydrazinylidene)methyl]phenol
14-Hpdhe(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 14-HPDHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
14(S)-Hpdhe(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 14(S)-HPDHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide
C17H33N3O3S (359.22425080000005)
(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate
A docosanoid anion that is the conjugate base of (13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,11E,13Z,16Z,19Z)-10-hydroperoxydocosa-4,7,11,13,16,19-hexaenoate
1-(4-methylphenyl)-2-[3-(4-methylphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-1-ium-1-yl]ethanone
(4Z,7S,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoate
13-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]tridecanoate
(5Z,7S,8E,10Z,13Z,15Z,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoate
(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosa-4,8,10,12,16,19-hexaenoate
10(R),17(R)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoate
(14S,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate
(14R,21R)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate
(14S,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate
(14R,21S)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoate
6-{3-[(1E,3E,5Z,7E,11Z)-9-hydroxytetradeca-1,3,5,7,11-pentaen-1-yl]oxiran-2-yl}hexanoate
(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate
12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxododecanoate
(11R)-11-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxododecanoate
(12R)-12-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxytridecanoate
(3Z,5S)-3-[(2E,6R,8E,10E,12E)-1-hydroxy-2,6-dimethyltetradeca-2,8,10,12-tetraenylidene]-5-(hydroxymethyl)pyrrolidine-2,4-dione
C21H29NO4 (359.20964740000005)
(1R,2R,4S,5S,7R,8R,9R,10S,13R,16S,17R)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol
(1R,2R,4S,5S,7R,8R,9R,10R,13R,16S,17R)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol
(1R,2S,4S,5S,7R,8R,9R,10R,13R,16S,17S)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol
2-(3-Hydroxybutoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide
C20H29N3O3 (359.22088040000006)
2-Trimethylsilyloxy-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide
(1R,4S,5S,7R,8R,9R,10R,13R,16S,17S)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.15,8.01,10.02,8.013,17]nonadecane-4,7,16-triol
gepirone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants Gepirone is a selective and affinitive 5-HT1A agonist. Gepirone binds selectively to 5-HT1A receptor binding site. Gepirone acts as an antidepressant agent can be used for anxiety and major depressive disorder research[1].
loxtidine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosahexaenoate
A hydroperoxydocosahexaenoate that is the conjugate base of (17S)-HPDoHE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
3-hydroxydodecanoylcarnitine
C19H37NO5 (359.26715920000004)
An O-acylcarnitine having 3-hydroxydodecanoyl as the acyl substituent.
(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoate
A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoate
A dihydroxydocosahexaenoate that is the conjugate base of (7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
oscr#22(1-)
A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#22, obtained by deprotonation of the carboxy group; major species at pH 7.3.
resolvin D5(1-)
A dihydroxydocosahexaenoate that is the conjugate base of resolvin D5, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoate
A docosanoid anion that is the conjugate base of (4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoate
A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoate
A docosanoid anion that is the conjugate base of 7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Tetracosatetraenoate
A polyunsaturated fatty acid anion that is the conjugate base of tetracosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
aspirin-triggered protectin D1(1-)
A dihydroxydocosahexaenoate that is the conjugate base of aspirin-triggered protectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoate
A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoate
A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoate
A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
asperparaline A
C20H29N3O3 (359.22088040000006)
An alkaloid isolated from Aspergillus aculeatus.
protectin D1(1-)
A dihydroxydocosahexaenoate that is the conjugate base of protectin D1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoate
A dihydroxydocosahexaenoate that is the conjugate base of (4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
CarE(12:0)
C19H37NO5 (359.26715920000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione
C20H29N3O3 (359.22088040000006)
(1r,2s,5r,8r,9r,10s,11r,13r,14s,15r,16r)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-2,11,14-triol
(1's,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione
C20H29N3O3 (359.22088040000006)
(3r,5s)-3-[(1r,2r,4as,8as)-2,3,6-trimethyl-1,2,4a,5,8,8a-hexahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-4,5-dihydropyrrole-2,3-diol
(4s)-4-amino-4-{[(1s,2s)-1-{[(1s)-1-carboxy-2-methylpropyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]-c-hydroxycarbonimidoyl}butanoic acid
C16H29N3O6 (359.20562540000003)
(1r,7r,10r,18s,22r,23s)-15-hydroxy-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricosan-4-one
7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl carbamoylformate
4-[(1s,2r,4as,6r,8ar)-1,3,6-trimethyl-2-propyl-4a,5,6,7,8,8a-hexahydro-2h-naphthalene-1-carbonyl]-3,5-dihydroxypyrrol-2-one
C21H29NO4 (359.20964740000005)
4-hydroxy-6-methoxy-3-methyl-2-(8-methyldeca-2,4,6-trien-2-yl)-2h,3h,4h-pyrano[3,2-c]pyridin-5-one
C21H29NO4 (359.20964740000005)
(1r,5r,6r,7r,8s,9r,13r,16s,17s)-11-ethyl-7,16-dihydroxy-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-4-one
4-[(1r,2r,4ar,6r,8ar)-1,3,6-trimethyl-2-propyl-4a,5,6,7,8,8a-hexahydro-2h-naphthalene-1-carbonyl]-3,5-dihydroxypyrrol-2-one
C21H29NO4 (359.20964740000005)
(2s,4e)-4-{[(1s,2r,4as,6r,8ar)-1,6-dimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-(hydroxymethyl)-2h-pyrrol-3-one
C21H29NO4 (359.20964740000005)
4,5,6,17-tetramethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene
C21H29NO4 (359.20964740000005)
(1s,5r,8r,10r,11s,14s,16r,17r)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-ol
(1s,2s,4s,5r,7r,8r,9s,10s,13s,16r,17s)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
(2s,4z)-4-{[(1s,4as,6r,8ar)-1,6-dimethyl-2-[(1e)-prop-1-en-1-yl]-4a,5,6,7,8,8a-hexahydro-2h-naphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-2-(hydroxymethyl)-2h-pyrrol-3-one
C21H29NO4 (359.20964740000005)
(4s,4ar,6s,7r,7as)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C21H29NO4 (359.20964740000005)
(1s,2s,4s,6r,7s,10r,11r)-6-hydroxy-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-8-one
2-{6,8-dihydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl}acetaldehyde
(1r,5r,8r,10s,11r,14s,16r,17r,18s)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-18-ol
11-ethyl-4,16-dihydroxy-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-7-one
methyl 3-[(1s,2r,3s,7r,10s,13s,14r)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-2-yl]propanoate
(1s,2s,4r,7s,8r,10r,11r)-8-hydroxy-13-(2-hydroxyethyl)-11-methyl-19-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-one
8-deoxy-14-dehydro-aconosine
{"Ingredient_id": "HBIN013704","Ingredient_name": "8-deoxy-14-dehydro-aconosine","Alias": "NA","Ingredient_formula": "C22H33NO3","Ingredient_Smile": "CCN1CC2CCC(C34C2CC(C31)C5CC(C6CC4C5C6=O)OC)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14994","TCMID_id": "5165","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
ajaconine
{"Ingredient_id": "HBIN014950","Ingredient_name": "ajaconine","Alias": "NA","Ingredient_formula": "C22H33NO3","Ingredient_Smile": "CC12CCCC34C1CC(C56C3CC(CC5)C(=C)C6O)OC4N(C2)CCO","Ingredient_weight": "359.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "782","TCMSP_id": "NA","TCM_ID_id": "7099;19458;21460","PubChem_id": "133562510","DrugBank_id": "NA"}
(1r,8s,10r)-8-ethoxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[8.4.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5,12-tetraen-3-ol
C21H29NO4 (359.20964740000005)
7''-ethyl-6-methyl-4'',7''-dihydro-3''h-dispiro[oxane-2,6'-[7,9,12]triazatricyclo[6.3.1.0⁴,¹²]dodecane-10',2''-oxepin]-7'-ene
C21H33N3O2 (359.25726380000003)
(1s,5r,8s,9s,11r,13r,14s,15s,17r,18s)-7-(2-hydroxyethyl)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,15-diol
(1r,2s,4s,6r,7r,8r,10s,11r,12r)-12-ethoxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-ene-6,8-diol
12-ethyl-14-methyl-6-methylidene-12-azahexacyclo[8.7.1.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]nonadecane-4,7,17-triol
(1s,2r,4s,5r,7r,8r,10s,11r,14r,17s,18r)-12-ethyl-14-methyl-6-methylidene-12-azahexacyclo[8.7.1.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]nonadecane-4,7,17-triol
(1s,2s,4s,6s,7r,8r,10r,11r)-13-[(1e)-2-hydroxyethenyl]-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecane-6,8-diol
(1'r,3s,3's,7'r,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione
C20H29N3O3 (359.22088040000006)
5-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-n-{[(1-hydroxy-3-methylbut-2-en-1-ylidene)amino]methanimidoyl}-3-methylpent-2-enimidic acid
C21H33N3O2 (359.25726380000003)
7-methoxy-n-(2-phenylethyl)tetradec-4-enimidic acid
5,8-dihydroxy-n-(1-hydroxy-3-methylpentan-2-yl)-4-methoxy-4,6-dimethyldec-2-enimidic acid
C19H37NO5 (359.26715920000004)
(1r,2s,5r,9r,10s,11r,13r,14s,15r,16r)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-2,11,14-triol
(4r,4as,6r,7s,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C21H29NO4 (359.20964740000005)
3-[(2e)-6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl]-4-methoxy-1-methylquinolin-2-one
C21H29NO4 (359.20964740000005)
(4s,4ar,6s,7r,7ar)-2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C21H29NO4 (359.20964740000005)
(4s)-4-[(1z,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole
C22H33NOS (359.22827280000007)
2-[(1s,2s,4s,6s,7r,8r,10r,11r)-6,8-dihydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde
(1r,2s,4s,6r,7s,10s,11r)-6-hydroxy-13-(2-hydroxyethyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-12-one
(1r,2s,5r,8s,9r,10s,11r,13r,14s,15s,16r)-7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-2,11,14-triol
(1s,2r,4r,7r,8s,9r,13s,16s,17r)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
(2s,3as,3bs,6s,6ar,7s,9ar,11ar)-7,8,11-trimethyl-6-(2-methylpropyl)-1h,2h,3h,6h,6ah,7h,9ah,11ah-indeno[5,4-d]isoindole-2,3a,4-triol
7-(2-hydroxyethyl)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,15-diol
4-(11-methoxytetradeca-1,5,7,13-tetraen-1-yl)-2-(2-methylcyclopropyl)-4,5-dihydro-1,3-thiazole
C22H33NOS (359.22827280000007)
(1s,2s,5s,6r,7s,10s,12r,16s)-7,8,12-trimethyl-5-(2-methylpropyl)-13-oxa-4-azapentacyclo[12.2.1.0²,⁶.0²,¹⁰.0¹²,¹⁶]heptadeca-3,8-diene-1,3-diol
(2e)-5-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-n-{[(1-hydroxy-3-methylbut-2-en-1-ylidene)amino]methanimidoyl}-3-methylpent-2-enimidic acid
C21H33N3O2 (359.25726380000003)
(1s,2s,4r,7r,10r,11r,18s)-18-hydroxy-13-(2-hydroxyethyl)-11-methyl-19-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-one
2,4,7-trimethyl-octahydrocyclopenta[c]pyridin-6-yl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
C21H29NO4 (359.20964740000005)
1,11-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,10h,11h,12h-cyclonona[d]isoindol-13-one
methyl 3-[(1s,2r,3r,7r,10s,11r,13s,14s)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]propanoate
methyl 3-{14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl}propanoate
3-[(1s,4r,5r,8r,9r,12s,13s,14s,18s)-8-hydroxy-5,9-dimethyl-11-azahexacyclo[9.6.1.0¹,¹⁴.0⁴,¹⁸.0⁵,¹³.0⁸,¹²]octadecan-13-yl]propanoic acid
(1r,2s,4r,5r,6s,8r,9r,10r,13r,16s,17r)-11-ethyl-4,16-dihydroxy-6,13-dimethyl-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecan-7-one
(2s)-n-[(2s)-1-(1h-indol-3-yl)-3-(propanoyloxy)propan-2-yl]-3-methyl-2-(methylamino)butanimidic acid
C20H29N3O3 (359.22088040000006)
methyl 3-{14-isopropyl-1-methyl-12-azatetracyclo[8.6.0.0²,¹³.0³,⁷]hexadec-3-en-2-yl}propanoate
(2r,3r,4r,5r)-2-[(1r)-5-{1,6-dioxaspiro[4.5]decan-7-yl}-1-hydroxypentyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol
(1s,3e,5s,10r)-15-ethyl-1,5-dihydroxy-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16)-dien-14-one
(1s,5r,8r,9s,11r,13r,14s,15s,17r,18s)-7-(2-hydroxyethyl)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,15-diol
methyl 3-[(1s,2r,3s,7r,10s,13s,14s)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-2-yl]propanoate
(4r)-4-[(1z,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole
C22H33NOS (359.22827280000007)
(1r,4s,5s,7r,8r,9r,10r,13r,16s)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
(1'r,2s,4's,6s,7''r,10'r)-7''-ethyl-6-methyl-4'',7''-dihydro-3''h-dispiro[oxane-2,6'-[7,9,12]triazatricyclo[6.3.1.0⁴,¹²]dodecane-10',2''-oxepin]-7'-ene
C21H33N3O2 (359.25726380000003)
3,5-dihydroxy-4-(1,3,6-trimethyl-2-propyl-4a,5,6,7,8,8a-hexahydro-2h-naphthalene-1-carbonyl)pyrrol-2-one
C21H29NO4 (359.20964740000005)
n-{[(2s,5e,6r,8r,9s,11s,12s)-8-(4-hydroxybutyl)-12-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-5-ylidene]methyl}ethanimidic acid
C21H33N3O2 (359.25726380000003)
4-[(1e,5e,7e,11r)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole
C22H33NOS (359.22827280000007)
7,8,12-trimethyl-5-(2-methylpropyl)-13-oxa-4-azapentacyclo[12.2.1.0²,⁶.0²,¹⁰.0¹²,¹⁶]heptadeca-3,8-diene-1,3-diol
n-{[(5e)-8-(4-hydroxybutyl)-12-(prop-2-en-1-yl)-1,7-diazatetracyclo[7.3.1.0²,⁷.0⁶,¹¹]tridecan-5-ylidene]methyl}ethanimidic acid
C21H33N3O2 (359.25726380000003)
(10r)-10-[(3s,5r,6r,7r,7ar)-6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one
methyl 3-[(1r,2s,3s,7s,10r,11s,13r,14s)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹¹]hexadecan-2-yl]propanoate
4-[(1z,5e,7e)-11-methoxytetradeca-1,5,7,13-tetraen-1-yl]-2-[(1r,2s)-2-methylcyclopropyl]-4,5-dihydro-1,3-thiazole
C22H33NOS (359.22827280000007)
2,2,2-trifluoro-1-[2-methyl-3-(tridec-5-en-1-yl)-4,5-dihydropyrrol-1-yl]ethanone
(1s,17s)-4,5,6,17-tetramethoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2(7),3,5,14-tetraene
C21H29NO4 (359.20964740000005)
7,8,11-trimethyl-6-(2-methylpropyl)-1h,2h,3h,6h,6ah,7h,9ah,11ah-indeno[5,4-d]isoindole-2,3a,4-triol
(1r,2s,4r,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
(4e,7s)-7-methoxy-n-(2-phenylethyl)tetradec-4-enimidic acid
(3s,3ar,4s,6as,11s,13ar)-1,11-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,10h,11h,12h-cyclonona[d]isoindol-13-one
(2r,4ar,7s,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl carbamoylformate
(3s,5s)-3-[(1s,2s,4ar,8ar)-2,3,6-trimethyl-1,2,4a,5,8,8a-hexahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-4,5-dihydropyrrole-2,3-diol
(1r,2r,4s,5r,7r,8r,9r,10r,13r,16s,17r)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
(2r,3r,4s)-4-hydroxy-6-methoxy-3-methyl-2-[(2e,4e,6e,8r)-8-methyldeca-2,4,6-trien-2-yl]-2h,3h,4h-pyrano[3,2-c]pyridin-5-one
C21H29NO4 (359.20964740000005)
(2r,3r,4r,5r)-2-[(1r)-4-{1,7-dioxaspiro[5.5]undecan-2-yl}-1-hydroxybutyl]-5-(hydroxymethyl)pyrrolidine-3,4-diol
8-ethoxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[8.4.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5,12-tetraen-3-ol
C21H29NO4 (359.20964740000005)
(1s,5r,8r,10r,11s,12r,14s,16r,17r)-7-(2-hydroxyethyl)-5-methyl-13-methylidene-9-oxa-7-azahexacyclo[8.6.2.2¹¹,¹⁴.0¹,⁸.0⁵,¹⁷.0¹¹,¹⁶]icosan-12-ol
3-(6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl)-4-methoxy-1-methylquinolin-2-one
C21H29NO4 (359.20964740000005)
methyl 4-[(1e)-2-acetyl-4-oxonon-1-en-1-yl]-6-propylpyridine-3-carboxylate
C21H29NO4 (359.20964740000005)
(2e,4r,5s,6s,8r)-5,8-dihydroxy-n-[(2s,3s)-1-hydroxy-3-methylpentan-2-yl]-4-methoxy-4,6-dimethyldec-2-enimidic acid
C19H37NO5 (359.26715920000004)
8-hydroxy-13-(2-hydroxyethyl)-11-methyl-19-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-6-one
2,2,2-trifluoro-1-{2-methyl-3-[(5z)-tridec-5-en-1-yl]-4,5-dihydropyrrol-1-yl}ethanone
(2r,4r,5r,7r,8r,13r,16s,17r)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
(3s,3ar,4s,6as,11r,13ar)-1,11-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,10h,11h,12h-cyclonona[d]isoindol-13-one
(3s,5s)-3-[(1s,2r,4as,8ar)-2,3,6-trimethyl-1,2,4a,5,8,8a-hexahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-4,5-dihydropyrrole-2,3-diol
(2s,3as,3bs,6s,6ar,7s,9as,11ar)-7,8-dimethyl-11-methylidene-6-(2-methylpropyl)-1h,2h,3h,6h,6ah,7h,9ah,10h,11ah-indeno[5,4-d]isoindole-2,3a,4-triol
(3s,5s)-3-[(1r,2r,4as,8as)-2,3,6-trimethyl-1,2,4a,5,8,8a-hexahydronaphthalene-1-carbonyl]-5-(2-methylpropyl)-4,5-dihydropyrrole-2,3-diol
15-ethyl-1,5-dihydroxy-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16)-dien-14-one
2-[(1s,2r,4s,6s,7r,8r,10s,11r)-6,8-dihydroxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecan-13-yl]acetaldehyde
3-[(1r,2r,7s,10r,11r,13r,15s,17r)-17-isopropyl-11-methyl-14-oxa-16-azapentacyclo[11.3.1.0²,¹¹.0³,⁷.0¹⁰,¹⁵]heptadec-3-en-2-yl]propanoic acid
(1's,2r,4'r,6r,7''s,10's)-7''-ethyl-6-methyl-4'',7''-dihydro-3''h-dispiro[oxane-2,6'-[7,9,12]triazatricyclo[6.3.1.0⁴,¹²]dodecane-10',2''-oxepin]-7'-ene
C21H33N3O2 (359.25726380000003)
12-ethoxy-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadec-13-ene-6,8-diol
(2r,4ar,7r,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl carbamoylformate
10-[6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one
13-(2-hydroxyethenyl)-11-methyl-5-methylidene-13-azapentacyclo[9.3.3.2⁴,⁷.0¹,¹⁰.0²,⁷]nonadecane-6,8-diol
3-{17-isopropyl-11-methyl-14-oxa-16-azapentacyclo[11.3.1.0²,¹¹.0³,⁷.0¹⁰,¹⁵]heptadec-3-en-2-yl}propanoic acid
(1s,2r,4r,5r,7r,8s,9r,10r,13s,16s,17r)-11-ethyl-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,7,16-triol
(1'r,3s,3's,7's,12's)-1,4',4',12',14'-pentamethyl-9',14'-diazaspiro[pyrrolidine-3,5'-tetracyclo[5.5.2.0¹,⁹.0³,⁷]tetradecane]-2,5,13'-trione
C20H29N3O3 (359.22088040000006)
methyl 4-(2-acetyl-4-oxonon-1-en-1-yl)-6-propylpyridine-3-carboxylate
C21H29NO4 (359.20964740000005)
(10r)-10-[(3s,5r,6r,7r)-6,7-dihydroxy-5-(hydroxymethyl)-hexahydro-1h-pyrrolizin-3-yl]-1,10-dihydroxydecan-5-one
7-ethyl-5-methyl-12-methylidene-7-azahexacyclo[7.6.2.2¹⁰,¹³.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]nonadecane-2,11,14-triol
(2s)-2-{[(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-4-methylpentylidene]amino}butanedioic acid
C16H29N3O6 (359.20562540000003)